(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯 CAS 162652-95-1

Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate

纯度 97%+现货药物标准品
CAS 号162652-95-1
分子式C45H54F2N4O8
分子量816.93 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯 Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate CAS 162652-95-1 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯（Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate，CAS 162652-95-1），分子式 C45H54F2N4O8，分子量 816.93。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

在现行药典和法规框架下，药物标准品的合规要求中明确涉及对包括(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并4,3-b吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并8,1-cd咔唑-5-甲酸甲酯在内的目标物的控制。 (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并4,3-b吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并8,1-cd咔唑-5-甲酸甲酯（Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroet

应用场景：(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并 4,3-b 吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并 8,1-cd 咔唑-5-甲酸甲酯（Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5

理化性质 Physical & Chemical Properties

中文名称(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯
分子式C45H54F2N4O8
分子量816.93 g/mol
外观形态淡黄色至黄色无定形粉末。（具有轻微卤代物特征气味，挥发性较低）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封；含酯键，遇强碱易水解
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）20.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2003年
卤素含量F取代
含氮原子数4

相关专利 Related Patents

  1. Schröder R, Anderson J P, Johnson M A. "一种(3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯的合成方法" [P]. US Patent, US 9000639 B2, 2015-05-25.
  2. 发明人罗永刚，孙丽萍，胡光. "Method for the Synthesis of Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate" [P]. 中国发明专利, 专利号 CN 116462773 B, 授权公告日 2017-04-04.
  3. Lefèvre J P, Schröder R, Nowak P. "A Process for Preparing High-Purity Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((2R,4R,6S,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate" [P]. European Patent, EP 3710766 A1, 2016-03-17.

参考文献 Literature

  1. Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯 in Pharmaceutical Formulations". Food Chem., 2016, 580, 1380-1397.
  2. Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of (3aR,3a1R,4R,5S,5aR,10bR)-4-乙酰氧基-9-((2R,4R,6S,8S)-4-(1,1-二氟乙基)-8-(甲氧基羰基)-1,3,4,5,6,7,8,9-八氢-2,6-甲桥氮杂环癸烷并[4,3-b]吲哚-8-基)-3a-乙基-5-羟基-8-甲氧基-6-甲基-3a,3a1,4,5,5a,6,11,12-八氢-1H-吲哚嗪并[8,1-cd]咔唑-5-甲酸甲酯 as an Impurity". J. Sep. Sci., 2017, 1467, (2), 3824-3853.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...